The U.S. Supreme Court unanimously ruled that Hikma’s “skinny label” generic version of Amarin’s Vascepa does not infringe Amarin’s patents, reversing a lower-court decision. The ruling preserves the skinny-label pathway, letting generics market the drug for non-infringing indications while patent protections remain in place for other uses. Amarin markets Vascepa for severe hypertriglyceridemia; FDA later expanded the label to less-severe triglyceride levels to reduce cardiovascular risk. Amarin argued Hikma’s marketing encouraged off-label prescribing across indications covered by its patents. The justices rejected that theory, finding Hikma did not take affirmative steps to induce infringement. The decision is likely to be felt beyond Vascepa, because it clarifies inducement standards in skinny-label litigation that often determines how quickly cheaper generics reach patients. For pharma, it sharpens the legal stakes around label strategy, marketing language, and patent scope.